Know Cancer

or
forgot password

Unrelated Donor Hematopoietic Stem Cell Transplantation After Nonmyeloablative Conditioning for Younger Patients With Hematologic Malignancies


Phase 2
15 Years
55 Years
Not Enrolling
Both
HEMATOLOGIC MALIGNANCIES

Thank you

Trial Information

Unrelated Donor Hematopoietic Stem Cell Transplantation After Nonmyeloablative Conditioning for Younger Patients With Hematologic Malignancies


Primary end points are treatment-related mortality and engraftment. Secondary end points are
regimen-related toxicities, graft-versus-host-disease, relapse, and overall survival.


Inclusion Criteria:



-Patients should have an unrelated donor who is matched for HLA-A and -B by serology and
for -DRB1 by molecular typing.

Exclusion Criteria:

- Patients should not have major illness or organ failure

- Patients must not have a psychiatric disorder or mental deficiency severe as to make
compliance with the treatment unlike, and making informed consent impossible.

- Patients must not be pregnant or lactating.

Type of Study:

Observational

Study Design:

Observational Model: Case-Only, Time Perspective: Prospective

Outcome Measure:

treatment-related mortality and engraftment

Outcome Time Frame:

all cause mortality

Safety Issue:

No

Principal Investigator

Kyoo-hyung Lee, doctor

Investigator Role:

Principal Investigator

Investigator Affiliation:

COSAH

Authority:

Korea: Food and Drug Administration

Study ID:

C-004

NCT ID:

NCT00770523

Start Date:

December 2003

Completion Date:

December 2008

Related Keywords:

  • Hematologic Malignancies
  • patients without comorbidity
  • Neoplasms
  • Hematologic Neoplasms

Name

Location